[Special Stock] Daesung Changtu Rises on Neofect's US Remote Medical Support News for COVID-19
Neofect Advances Remote Medical System for COVID-19 in the US
Investors Daesung Changtu, Company K Show Upward Trend
[Asia Economy Reporter Minwoo Lee] Following the news that Neofect's telemedicine system has been approved by the Massachusetts state government in the United States, investors such as Daesung Venture Investment and Company K Partners are also showing an upward trend.
As of 1:35 PM on the 18th, Daesung Venture Investment reached 1,435 KRW, up 10.38% from the previous day. This comes after news that Neofect, in which they previously invested, is expected to benefit from the Massachusetts state government's telemedicine support measures in preparation for the large-scale spread of the novel coronavirus infection (COVID-19). Company K, which also invested in Neofect, recorded 5,770 KRW at 1:25 PM on the same day, up 29.81% from the previous day.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Meanwhile, Neofect recently received an official approval letter from the Massachusetts state government allowing insurance coverage for telemedicine costs related to COVID-19 and is reportedly reorganizing its telemedicine system. Accordingly, Neofect recorded 3,675 KRW at around 10:44 AM on the same day, up 29.86% from the previous day.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
